Fixing Psychiatric Research At A University
By Ed Silverman,
Pharmalot
| 03. 20. 2013
[Op-Ed]
Over the past few years, University of Minnesota bioethicist Carl Elliott has explored a complicated and increasingly controversial episode over a clinical trial and a suicide. The saga has involved researchers at his own university, a major drugmaker, allegations of misconduct, a lawsuit and various investigations. But answers to questions continue to raise more questions, so he has initiated an online petition asking the Minnesota governor to probe his employer. He explains why…The University of Minnesota has turned me into an activist against it. Let me confess right away that this is not a role for which I am naturally suited. I have never staged a protest or addressed a rally. Nor have I ever marched with a sign. On the occasions when I am required to give public lectures, I sweat nervously and display an embarrassing tendency to pause in mid-sentence for uncomfortably long periods. But even I can work up a pretty good head of anger when I see cruelty or injustice, and this is especially true when the injustice is deliberately inflicted and the victim cannot...
Related Articles
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Jorge Barrera and Rachel Houlihan, CBC | 04.09.2024
A Canadian DNA laboratory knowingly delivered prenatal paternity test results that routinely identified the wrong biological fathers — ruling out the real dads — and left a trail of shattered lives around the globe, a CBC News investigation has found...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...